Neurodegenerative Diseases Drugs Market Size, Share and Industry Analysis By Drug Class (Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others), By Disease Indication (Multiple Sclerosis, Parkinson’s Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA), Others), By Route of Administration (Oral, Injection, Transdermal, Others), By End User and Regional Forecast 2026-2034

Last Updated: December 22, 2025 | Format: PDF | Report ID: FBI100661

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Unit	Value (USD Billion)
Growth Rate	CAGR of 5.05% from 2026 to 2034
	By Drug Class Immunomodulator Interferons Decarboxylase Inhibitors Dopamine Agonists Others
Segmentation	By Disease Indication Multiple Sclerosis Parkinson’s Disease Alzheimer's Disease Spinal Muscular Atrophy (SMA) Others
	By Route of Administration Oral Injection Transdermal
	By End User Hospital Pharmacy Retail Pharmacy Online Pharmacy
	By Geography North America (USA and Canada) Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) Latin America (Brazil, Mexico and Rest of Latin America) Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)